Persistent Presence of the Anti-Myelin Oligodendrocyte Glycoprotein Autoantibody in a Pediatric Case of Acute Disseminated Encephalomyelitis Followed by Optic Neuritis

Abstract

We report the case of a 5-year-old Japanese girl who initially had acute disseminated encephalomyelitis (ADEM) and was positive for the myelin oligodendrocyte glycoprotein (MOG) antibodies and developed unilateral optic neuritis (ON) 71 days after ADEM onset. The patient's serum was positive for the anti-MOG antibodies from the onset of ADEM to the development of ON. This phenotype has been reported in only two previous articles, and the specific mechanism of action of the anti-MOG antibodies is not yet understood. Our case suggests that the anti-MOG antibody can be associated with the pathogenesis of ADEM followed by ON. Thus, patients with ADEM who test positive for the anti-MOG antibody may be at risk of developing subsequent ON.

Keywords

MOG - ADEM - ON - pediatrics

• References

• 1 Krupp LB, Banwell B, Tenembaum S ; International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68 (16) (Suppl. 02) S7-S12
• 2 Huppke P, Rostasy K, Karenfort M , et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler 2013; 19 (7) 941-946
• 3 Rostásy K, Mader S, Hennes EM , et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013; 19 (8) 1052-1059
• 4 O'Connor KC, McLaughlin KA, De Jager PL , et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007; 13 (2) 211-217
• 5 McLaughlin KA, Chitnis T, Newcombe J , et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009; 183 (6) 4067-4076
• 6 Pröbstel AK, Dornmair K, Bittner R , et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011; 77 (6) 580-588
• 7 Di Pauli F, Mader S, Rostasy K , et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 2011; 138 (3) 247-254
• 8 Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci U S A 2005; 102 (39) 13992-13997
• 9 Brilot F, Dale RC, Selter RC , et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009; 66 (6) 833-842
• 10 Amiguet P, Gardinier MV, Zanetta JP, Matthieu JM. Purification and partial structural and functional characterization of mouse myelin/oligodendrocyte glycoprotein. J Neurochem 1992; 58 (5) 1676-1682
• 11 Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013; 9 (8) 455-461
• 12 Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard CC, Ben-Nun A. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 1993; 92 (6) 2602-2608
• 13 Kezuka T, Usui Y, Yamakawa N , et al. Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. J Neuroophthalmol 2012; 32 (2) 107-110